Ocugen

Ocugen’s Third Quarter: A Crucible of Clinical Data and Capital Concerns

April 23, 2026

Ocugen Navigates a Critical Juncture with Cash and Clinical Catalysts

angelina - April 12, 2026

Analyst Confidence Rises for Ocugen’s Gene Therapy Pipeline

angelina - April 3, 2026

Ocugen Sets Ambitious Regulatory Timeline for Gene Therapy Pipeline

Brett Shapiro - March 28, 2026

Ocugen Set to Unveil Full Phase 2 Trial Results for Key Gene Therapy

Brett Shapiro - March 24, 2026

Analyst Sentiment Shifts as Ocugen’s Clinical Pipeline Gains Momentum

kashif hafeez - March 20, 2026

Ocugen’s Aggressive Development Pipeline Faces Critical Data Readouts

kashif hafeez - March 19, 2026

Ocugen Shares Surge on Analyst Optimism and Upcoming Clinical Catalysts

March 14, 2026

Analyst Optimism Fuels Momentum for Ocugen’s Clinical Pipeline

angelina - March 12, 2026

Ocugen Reports Key Clinical and Financial Milestones

Brett Shapiro - March 6, 2026

Ocugen Achieves Key Milestone in Gene Therapy Trial

angelina - March 3, 2026

A Pivotal Week for Ocugen as Financial and Clinical Catalysts Converge

angelina - February 27, 2026

Ocugen’s Strategic Pivot: A New Financial Leader for the Commercial Leap

kashif hafeez - February 11, 2026

Ocugen Bolsters Leadership with Gene Therapy Expert Ahead of Pivotal Year

kashif hafeez - February 10, 2026

Ocugen’s Pivotal Year: Key Clinical Milestones Set for 2026

Brett Shapiro - February 9, 2026

12 3 Page 1 of 3